Developer docs
API playgroundTry for free, no card

Search company profiles

Scipher Medicine

Full company profile

uuid00003xj

Namestring
Scipher Medicine
Legal namestring
Scipher Medicine Corporation
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Scipher Medicine is a precision immunology company that develops molecular diagnostic tests and AI-driven biomarker platforms for autoimmune diseases. The company's core technology is the Spectra AI Platform, which applies network science and proprietary AI algorithms to a human interactome map covering 89% of human cell proteins, enabling biomarker discovery and patient stratification for therapy selection. Its commercial diagnostic portfolio centers on the Prism franchise of laboratory-developed tests — PrismRA (commercially available blood-based test predicting TNFi non-response in rheumatoid arthritis, Medicare-covered since 2023), PrismUC (tissue-based test for ulcerative colitis), and research-phase tests PrismPSA (psoriatic arthritis) and PrismMS (multiple sclerosis) — backed by the PRoBeNet biomarker discovery framework and a data lake containing molecular samples from 30,000+ patients and clinical data on 300,000+ autoimmune patients.

Scipher serves two primary customer segments: healthcare providers (rheumatologists and gastroenterologists who order Prism tests to guide therapy selection and navigate step therapy), and pharmaceutical and biotech companies that license the platform's data, biomarkers, and AI capabilities for clinical trial design, patient stratification, and companion diagnostic co-development. Revenue is generated through diagnostic test billing to payers (including Medicare and commercial insurers), research collaborations, data licensing, and co-development agreements. The company has established strategic pharma partnerships with Galapagos, Ionis, Eli Lilly, Optum, Aitia, Savant Bio, Maxymune Therapeutics, Senelix, and a top-3 pharmaceutical company, and operates a distribution alliance with Grupo Amarey for Latin America.

Founded in 2013 by Drs. Joseph Loscalzo and Albert-László Barabási from research initiated in 2003, Scipher is headquartered in Waltham, Massachusetts, and is venture-backed through Series D with roughly $227 million disclosed in funding from Khosla Ventures, Northpond Ventures, United Health Group, Optum Ventures, Blue Owl, aMoon, Cowen, and other institutional investors. The company acquired CrossBridge in January 2023 to enhance real-time data capabilities and launched ClinicalTrialRank.com in August 2025 to extend its AI platform into clinical trial failure prediction for pharmaceutical R&D.

Short descriptiontext

Scipher Medicine is a precision immunology company combining network science and AI to develop molecular diagnostic tests and biomarker platforms for autoimmune diseases, serving rheumatologists, gastroenterologists, and pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision immunology, molecular diagnostics, therapy response prediction, network medicine, autoimmune disease testing
Industry3 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAJ
Real-World Evidence (RWE) & Outcomes Analytics for Precision Therapies
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Precision Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Testing Services
TypeOne Time License
Description

Scipher generates revenue through laboratory-developed tests (LDTs) including PrismRA, PrismUC, and PrismPSA. These blood-based and tissue-based tests are prescribed by physicians and billed to payers (including Medicare) for predicting therapy response in autoimmune disease patients.

sciphermedicine.com
2Pharmaceutical Partnerships
TypeSubscription Recurring
Description

Scipher partners with pharmaceutical companies for drug development, clinical trial design, patient stratification, and target discovery. Revenue comes from research collaborations, data licensing, and co-development agreements.

sciphermedicine.com
3Data Licensing and Insights
TypeData Monetisation
Description

Scipher's extensive data lake (30K+ molecular samples, 300K+ patient clinical data) enables data licensing and insights services to pharmaceutical and biotech partners for drug discovery and development.

sciphermedicine.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1PrismRA
Description

Blood-based molecular signature response classifier test for rheumatoid arthritis that predicts TNFi non-response

sciphermedicine.com
+6 more records
Core offering1 text field

Scipher Medicine develops and commercializes laboratory-developed molecular signature response classifier tests (PrismRA, PrismUC) that predict patient response to biologic therapies in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. Its Spectra AI Platform combines a proprietary human interactome map with AI algorithms to power these diagnostic tests and enable biomarker discovery, patient stratification, and pharmaceutical drug development collaborations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 90% of RA patients who fail methotrexate are prescribed anti-TNF therapies, but most do not respond to treatment
+6 more records
Product overview1 text field

Scipher Medicine offers a platform-plus-diagnostics portfolio centered on the Spectra AI Platform, which combines network science and AI to map autoimmune diseases at the molecular level. The platform enables biomarker discovery and patient stratification, powering a suite of Prism laboratory-developed diagnostic tests: PrismRA (commercially available for rheumatoid arthritis), PrismUC (in development for ulcerative colitis), PrismPsA (in research for psoriatic arthritis), and PrismMS (early research for multiple sclerosis). Supporting products include the PRoBeNet biomarker discovery framework and ClinicalTrialRank.com for clinical trial risk assessment. The Data Lake provides the foundational molecular and clinical data infrastructure across 300,000+ autoimmune patients.

Product and service7 records
1PrismRA
CategoryDiagnostic Test
Description

Blood-based molecular signature response classifier test that predicts inadequate response to TNF inhibitor (TNFi) therapies in rheumatoid arthritis patients, enabling personalized treatment selection from day one. Uses 23 biologic features including 19 gene transcripts, 1 serologic marker, and 3 clinical features.

2PrismUC
CategoryDiagnostic Test
Description

Tissue-based molecular signature response classifier test being developed for ulcerative colitis patients to guide therapy decisions for those not reaching treatment goals through corticosteroids alone.

3PrismPsA
CategoryDiagnostic Test
Description

Blood-based molecular signature response classifier test in research phase for psoriatic arthritis, designed to guide treatment selection and help patients get on the right medication for their biology sooner.

4PrismMS
CategoryDiagnostic Test
Description

Early-stage research initiative for multiple sclerosis using the Spectra platform's database and network map to tackle the treatment pathway for MS.

5Spectra AI Platform
CategoryAI Platform
Description

AI-driven platform combining network science and machine learning to map autoimmune diseases at the molecular level, enabling patient stratification, biomarker discovery, target identification, and identification of appropriate treatment pathways for pharmaceutical and biotech partners.

6ClinicalTrialRank.com
CategoryAI Platform
Description

AI-driven platform that predicts clinical trial failure by analyzing drug targets and disease biology using network-based analysis to help de-risk investment decisions in drug development.

7PRoBeNet
CategoryBiomarker Discovery Framework
Description

Predictive Response Biomarkers using Network medicine framework that discovers treatment-response-predicting biomarkers by analyzing protein-protein interaction networks and disease signatures, using the Personalized PageRank algorithm on the human interactome.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration signed in 2020 focused on inflammatory bowel disease. Galapagos in-licensed novel drug targets from Scipher in 2022. Galapagos is a Belgian biopharmaceutical company.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multi-target partnership signed in 2023 with Ionis Pharmaceuticals, a leader in RNA-targeted therapeutics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Eli Lilly and Company for therapeutic development and commercialization.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Aitia (formerly twoXAR) for biomarker discovery and validation using AI-driven approaches.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Optum for healthcare data and analytics integration.

6Senelix
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration announced March 2026 to advance SL300 development (CHI3L1 antibody), focusing on precision medicine and co-developing a companion diagnostic using Scipher's AI-driven Spectra platform.

sciphermedicine.com
7Maxymune Therapeutics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration announced September 2025 to accelerate target discovery in autoimmune and inflammatory diseases.

sciphermedicine.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Expanded strategic partnership announced July 2025 to build the world's most advanced clinico-genomic dataset in rheumatoid arthritis. Savant Bio is a Roivant-backed health data infrastructure company.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Strategic alliance announced June 2025 to bring precision medicine to Latin America. Grupo Amarey is a leading company in representation and distribution of technologies, solutions, and services for the healthcare industry.

10Top-3 Pharmaceutical Company
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration announced June 2025 to integrate precision medicine into clinical trial design, integrating Scipher's PrismRA for therapy response segmentation.

sciphermedicine.com
Strategic tierCoreTypeOthers
Description

Acquired in January 2023 to enhance capabilities in real-time data collection and patient treatment mapping for autoimmune diseases. CrossBridge is a data, analytics, and software company.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Exagen develops blood-based molecular diagnostic tests for autoimmune diseases such as lupus and rheumatoid arthritis. Directly comparable to Scipher's PrismRA as a precision immunology diagnostics company serving rheumatologists.

TypeDirect peer
Description

Adaptive Biotechnologies uses immune repertoire sequencing and AI for immune-mediated disease diagnostics and pharma partnerships (immune profiling, MRD). Comparable as a molecular immunology platform with pharma data monetization.

TypeDirect peer
Description

Myriad develops molecular diagnostic tests across multiple disease areas including autoimmune (Vectra DA for RA disease activity). Closely comparable as a specialty molecular diagnostics company with parallel pharma partnership channels.

TypeDirect peer
Description

Veracyte is a genomic diagnostics company that develops molecular tests to resolve diagnostic ambiguity and inform treatment decisions. Comparable to Scipher's biomarker-driven precision diagnostics model.

TypeDirect peer
Description

Caris offers AI-driven molecular profiling and precision medicine testing combined with a large clinico-genomic database for pharma partnerships. Directly comparable in business model (molecular diagnostics plus pharma data/biomarker services).

6Tempus Labs
TypeBroad incumbent
Description

Tempus is an AI-driven precision medicine company with broad molecular testing, a large clinical+molecular data library, and pharma data services. Overlapping with Scipher's Spectra platform but operating at a much larger scale.

TypeBroad incumbent
Description

Exact Sciences is a leading molecular diagnostics company (Cologuard, Oncotype) with deep payer relationships, large clinical lab operations, and pharma services. A scaled incumbent with comparable molecular diagnostics capability.

TypeBroad incumbent
Description

Foundation Medicine provides comprehensive genomic profiling and pharma data services. Comparable as a molecular profiling + pharma partnership model, though oncology-focused and a subsidiary of Roche.

TypeBroad incumbent
Description

Quest Diagnostics is one of the largest clinical reference laboratories offering autoimmune and specialty diagnostic testing with extensive payer coverage. Broad incumbent competing with Scipher's precision immunology tests.

TypeBroad incumbent
Description

Labcorp is a leading global clinical laboratory network offering autoimmune and specialty diagnostics. Broad incumbent with extensive payer relationships that could distribute or compete with Scipher's precision tests.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scipher Medicine

Precision Diagnosticssciphermedicine.com

Scipher Medicine is a precision immunology company combining network science and AI to develop molecular diagnostic tests and biomarker platforms for autoimmune diseases, serving rheumatologists, gastroenterologists, and pharmaceutical partners.

What Scipher Medicine does

Scipher Medicine is a precision immunology company that develops molecular diagnostic tests and AI-driven biomarker platforms for autoimmune diseases. The company's core technology is the Spectra AI Platform, which applies network science and proprietary AI algorithms to a human interactome map covering 89% of human cell proteins, enabling biomarker discovery and patient stratification for therapy selection. Its commercial diagnostic portfolio centers on the Prism franchise of laboratory-developed tests — PrismRA (commercially available blood-based test predicting TNFi non-response in rheumatoid arthritis, Medicare-covered since 2023), PrismUC (tissue-based test for ulcerative colitis), and research-phase tests PrismPSA (psoriatic arthritis) and PrismMS (multiple sclerosis) — backed by the PRoBeNet biomarker discovery framework and a data lake containing molecular samples from 30,000+ patients and clinical data on 300,000+ autoimmune patients.

Scipher serves two primary customer segments: healthcare providers (rheumatologists and gastroenterologists who order Prism tests to guide therapy selection and navigate step therapy), and pharmaceutical and biotech companies that license the platform's data, biomarkers, and AI capabilities for clinical trial design, patient stratification, and companion diagnostic co-development. Revenue is generated through diagnostic test billing to payers (including Medicare and commercial insurers), research collaborations, data licensing, and co-development agreements. The company has established strategic pharma partnerships with Galapagos, Ionis, Eli Lilly, Optum, Aitia, Savant Bio, Maxymune Therapeutics, Senelix, and a top-3 pharmaceutical company, and operates a distribution alliance with Grupo Amarey for Latin America.

Founded in 2013 by Drs. Joseph Loscalzo and Albert-László Barabási from research initiated in 2003, Scipher is headquartered in Waltham, Massachusetts, and is venture-backed through Series D with roughly $227 million disclosed in funding from Khosla Ventures, Northpond Ventures, United Health Group, Optum Ventures, Blue Owl, aMoon, Cowen, and other institutional investors. The company acquired CrossBridge in January 2023 to enhance real-time data capabilities and launched ClinicalTrialRank.com in August 2025 to extend its AI platform into clinical trial failure prediction for pharmaceutical R&D.

Scipher Medicine firmographics

Firmographics
Name
Scipher Medicine
Legal name
Scipher Medicine Corporation
Website
https://sciphermedicine.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Scipher Medicine is a precision immunology company combining network science and AI to develop molecular diagnostic tests and biomarker platforms for autoimmune diseases, serving rheumatologists, gastroenterologists, and pharmaceutical partners.
Ownership category
akta.pro rank

Scipher Medicine industry classification

Industry
Product category
Precision Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAJ
Real-World Evidence (RWE) & Outcomes Analytics for Precision Therapies

Keywords

  • Precision immunology
  • Molecular diagnostics
  • Therapy response prediction
  • Network medicine
  • Autoimmune disease testing

Where Scipher Medicine is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Scipher Medicine business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Diagnostic Testing Services: Scipher generates revenue through laboratory-developed tests (LDTs) including PrismRA, PrismUC, and PrismPSA. These blood-based and tissue-based tests are prescribed by physicians and billed to payers (including Medicare) for predicting therapy response in autoimmune disease patients.
  2. Pharmaceutical Partnerships: Scipher partners with pharmaceutical companies for drug development, clinical trial design, patient stratification, and target discovery. Revenue comes from research collaborations, data licensing, and co-development agreements.
  3. Data Licensing and Insights: Scipher's extensive data lake (30K+ molecular samples, 300K+ patient clinical data) enables data licensing and insights services to pharmaceutical and biotech partners for drug discovery and development.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Scipher Medicine product offering

Product offering

Core offering

Scipher Medicine develops and commercializes laboratory-developed molecular signature response classifier tests (PrismRA, PrismUC) that predict patient response to biologic therapies in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. Its Spectra AI Platform combines a proprietary human interactome map with AI algorithms to power these diagnostic tests and enable biomarker discovery, patient stratification, and pharmaceutical drug development collaborations.

Product overview

Scipher Medicine offers a platform-plus-diagnostics portfolio centered on the Spectra AI Platform, which combines network science and AI to map autoimmune diseases at the molecular level. The platform enables biomarker discovery and patient stratification, powering a suite of Prism laboratory-developed diagnostic tests: PrismRA (commercially available for rheumatoid arthritis), PrismUC (in development for ulcerative colitis), PrismPsA (in research for psoriatic arthritis), and PrismMS (early research for multiple sclerosis). Supporting products include the PRoBeNet biomarker discovery framework and ClinicalTrialRank.com for clinical trial risk assessment. The Data Lake provides the foundational molecular and clinical data infrastructure across 300,000+ autoimmune patients.

Differentiator

Problem solved

Functional benefit

Brands

  • PrismRA: Blood-based molecular signature response classifier test for rheumatoid arthritis that predicts TNFi non-response
  • PrismUC
  • PrismPSA
  • PrismMS
  • Spectra AI Platform
  • PRoBeNet
  • ClinicalTrialRank.com

Products and services

  • PrismRA Blood-based molecular signature response classifier test that predicts inadequate response to TNF inhibitor (TNFi) therapies in rheumatoid arthritis patients, enabling personalized treatment selection from day one. Uses 23 biologic features including 19 gene transcripts, 1 serologic marker, and 3 clinical features.
  • PrismUC Tissue-based molecular signature response classifier test being developed for ulcerative colitis patients to guide therapy decisions for those not reaching treatment goals through corticosteroids alone.
  • PrismPsA Blood-based molecular signature response classifier test in research phase for psoriatic arthritis, designed to guide treatment selection and help patients get on the right medication for their biology sooner.
  • PrismMS Early-stage research initiative for multiple sclerosis using the Spectra platform's database and network map to tackle the treatment pathway for MS.
  • Spectra AI Platform AI-driven platform combining network science and machine learning to map autoimmune diseases at the molecular level, enabling patient stratification, biomarker discovery, target identification, and identification of appropriate treatment pathways for pharmaceutical and biotech partners.
  • ClinicalTrialRank.com AI-driven platform that predicts clinical trial failure by analyzing drug targets and disease biology using network-based analysis to help de-risk investment decisions in drug development.
  • PRoBeNet Predictive Response Biomarkers using Network medicine framework that discovers treatment-response-predicting biomarkers by analyzing protein-protein interaction networks and disease signatures, using the Personalized PageRank algorithm on the human interactome.

Quantifiable outcome

  • 90% of RA patients who fail methotrexate are prescribed anti-TNF therapies, but most do not respond to treatment
  • +6 more outcomes

Companies that use Scipher Medicine

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Scipher Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Scipher Medicine partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core.

  • GalapagoscoreStrategic or Co-development PartnerCollaboration signed in 2020 focused on inflammatory bowel disease. Galapagos in-licensed novel drug targets from Scipher in 2022. Galapagos is a Belgian biopharmaceutical company.
  • IoniscoreStrategic or Co-development PartnerMulti-target partnership signed in 2023 with Ionis Pharmaceuticals, a leader in RNA-targeted therapeutics.
  • Eli LillycoreStrategic or Co-development PartnerPartnership with Eli Lilly and Company for therapeutic development and commercialization.
  • AitiacoreStrategic or Co-development PartnerPartnership with Aitia (formerly twoXAR) for biomarker discovery and validation using AI-driven approaches.
  • OptumcoreStrategic or Co-development PartnerPartnership with Optum for healthcare data and analytics integration.
  • SenelixcoreStrategic or Co-development PartnerStrategic collaboration announced March 2026 to advance SL300 development (CHI3L1 antibody), focusing on precision medicine and co-developing a companion diagnostic using Scipher's AI-driven Spectra platform.
  • Maxymune TherapeuticscoreStrategic or Co-development PartnerStrategic collaboration announced September 2025 to accelerate target discovery in autoimmune and inflammatory diseases.
  • Savant BiocoreStrategic or Co-development PartnerExpanded strategic partnership announced July 2025 to build the world's most advanced clinico-genomic dataset in rheumatoid arthritis. Savant Bio is a Roivant-backed health data infrastructure company.
  • Grupo AmareycoreChannel Partner/ Reseller/ DistributorStrategic alliance announced June 2025 to bring precision medicine to Latin America. Grupo Amarey is a leading company in representation and distribution of technologies, solutions, and services for the healthcare industry.
  • Top-3 Pharmaceutical CompanycoreStrategic or Co-development PartnerCollaboration announced June 2025 to integrate precision medicine into clinical trial design, integrating Scipher's PrismRA for therapy response segmentation.
  • CrossBridgecoreOthersAcquired in January 2023 to enhance capabilities in real-time data collection and patient treatment mapping for autoimmune diseases. CrossBridge is a data, analytics, and software company.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Scipher Medicine competitors and assessment

Company assessment

Direct peers

  • Exagen: Exagen develops blood-based molecular diagnostic tests for autoimmune diseases such as lupus and rheumatoid arthritis. Directly comparable to Scipher's PrismRA as a precision immunology diagnostics company serving rheumatologists.
  • Adaptive Biotechnologies: Adaptive Biotechnologies uses immune repertoire sequencing and AI for immune-mediated disease diagnostics and pharma partnerships (immune profiling, MRD). Comparable as a molecular immunology platform with pharma data monetization.
  • Myriad Genetics: Myriad develops molecular diagnostic tests across multiple disease areas including autoimmune (Vectra DA for RA disease activity). Closely comparable as a specialty molecular diagnostics company with parallel pharma partnership channels.
  • Veracyte: Veracyte is a genomic diagnostics company that develops molecular tests to resolve diagnostic ambiguity and inform treatment decisions. Comparable to Scipher's biomarker-driven precision diagnostics model.
  • Caris Life Sciences: Caris offers AI-driven molecular profiling and precision medicine testing combined with a large clinico-genomic database for pharma partnerships. Directly comparable in business model (molecular diagnostics plus pharma data/biomarker services).

Broad incumbents

  • Tempus Labs: Tempus is an AI-driven precision medicine company with broad molecular testing, a large clinical+molecular data library, and pharma data services. Overlapping with Scipher's Spectra platform but operating at a much larger scale.
  • Exact Sciences: Exact Sciences is a leading molecular diagnostics company (Cologuard, Oncotype) with deep payer relationships, large clinical lab operations, and pharma services. A scaled incumbent with comparable molecular diagnostics capability.
  • Foundation Medicine: Foundation Medicine provides comprehensive genomic profiling and pharma data services. Comparable as a molecular profiling + pharma partnership model, though oncology-focused and a subsidiary of Roche.
  • Quest Diagnostics: Quest Diagnostics is one of the largest clinical reference laboratories offering autoimmune and specialty diagnostic testing with extensive payer coverage. Broad incumbent competing with Scipher's precision immunology tests.
  • Laboratory Corporation of America (Labcorp): Labcorp is a leading global clinical laboratory network offering autoimmune and specialty diagnostics. Broad incumbent with extensive payer relationships that could distribute or compete with Scipher's precision tests.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Scipher Medicine social profiles

Digital presence

Scipher Medicine compliance and trust

Trust signal

Compliance1 record

Scipher Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scipher Medicine leadership team

Management profile

Number of profiles

Profiles11 records

Scipher Medicine subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Scipher Medicine funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scipher Medicine M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scipher Medicine

What does Scipher Medicine do?

Scipher Medicine develops and commercializes laboratory-developed molecular signature response classifier tests (PrismRA, PrismUC) that predict patient response to biologic therapies in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. Its Spectra AI Platform combines a proprietary human interactome map with AI algorithms to power these diagnostic tests and enable biomarker discovery, patient stratification, and pharmaceutical drug development collaborations.

Is Scipher Medicine a public or private company?

Scipher Medicine is a private company. It is classified as venture growth investor backed and is currently operating.

When was Scipher Medicine founded?

Scipher Medicine was founded in 2013. It employs 11 to 50 people.

Where is Scipher Medicine based?

Scipher Medicine is headquartered in Burlington, United States, in the North America region.

How does Scipher Medicine make money?

Three revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are pharmaceutical Partnerships and data Licensing and Insights.

Who are Scipher Medicine's main competitors?

Direct peers on record are Exagen, Adaptive Biotechnologies, Myriad Genetics, Veracyte and Caris Life Sciences. Broad incumbents are Tempus Labs, Exact Sciences, Foundation Medicine, Quest Diagnostics and Laboratory Corporation of America (Labcorp).

Does Scipher Medicine have an API?

No public API is recorded for Scipher Medicine.

What industry is Scipher Medicine in?

Scipher Medicine's product category is Precision Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation). Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireScipher Medicine and Grupo Amarey Announce First PrismRA® Patient Tests Completed in ColombiaScipher Medicine and Grupo Amarey completed the first PrismRA patient tests in Colombia, marking the first time the precision medicine test entered the country. The test, approved for CMS reimbursement, helps rheumatologists select effective treatments for rheumatoid arthritis. The companies plan to expand PrismRA use across Latin America.Business & FinancialScipher Medicine And Grupo Amarey Announce First Prismra® Patient Tests Completed In ColombiaScipher Medicine and Grupo Amarey completed the first PrismRA patient tests in Colombia, marking the test's first use in the country. The molecular test, approved for CMS reimbursement, helps rheumatologists select effective treatments for rheumatoid arthritis. The partnership aims to expand precision medicine access across Latin America.Business & FinancialScipher Medicine Launches Prismtcelltm, The Next Molecular Treatment Response Signature, For Abatacept In Rheumatoid ArthritisScipher Medicine announced an early physician access program for PrismTcell, a blood-based test predicting response to abatacept in rheumatoid arthritis. The test showed about a two-fold higher ACR50 response rate in MTRS-selected patients. Early access is expected in Q1 2027, with data presented at ACR Convergence 2026.PharmExecPharmaceutical Executive Daily: FDA Approves EnnumoThe FDA approved Ennumo, a biosimilar to Neulasta developed by Accord BioPharma, for use in reducing febrile neutropenia incidence and increasing survival in specific cancer and radiation exposure patients. Concurrently, Chemomab Therapeutics and Scipher Medicine announced a merger valued at $150 million to combine antibody technology with AI platforms, while Teva secured global licensing rights from Polpharma Biologics for an Ocrevus biosimilar. Cencora analyst Alina Chesnokova highlighted the industry shift toward cold chain-dependent specialty therapies requiring new commercialization strategies.GrafaChemomab reports $2.2 million Q2 lossChemomab Therapeutics reported a second-quarter 2026 net loss of $2.2 million and advanced its proposed all-stock merger with Scipher Medicine, which would result in a combined entity valued at approximately $150 million. The deal includes a concurrent $30 million private placement, and the merged company plans to initiate Phase 2 trials for nebokitug in rheumatoid arthritis during the first half of 2027.Quiver QuantitativeChemomab Therapeutics Advances Proposed Merger With Scipher Medicine to Launch Nebokitug Rheumatoid Arthritis Trial | CMMB Stock NewsChemomab Therapeutics is advancing its proposed merger with Scipher Medicine, aiming to develop nebokitug for rheumatoid arthritis, with the merger expected to close by the end of 2026. The market for rheumatoid arthritis is valued at $24 billion, and nebokitug is positioned to potentially be the first new treatment mechanism approved in the U.S. since 2012, with a Phase 2 trial planned for early 2027. Following the merger, the combined entity will operate as Scipher Medicine Corporation and will be valued at $150 million, supported by a $30 million private placement.Stock TitanProposed Chemomab-Scipher Merger: $150M ValuationChemomab Therapeutics announced the advancement of its proposed merger with Scipher Medicine, which combines their drug candidates and AI platforms to develop nebokitug for rheumatoid arthritis. The combined entity is valued at $150 million prior to a concurrent $30 million private placement, with closing expected by the end of 2026 following SEC review. This transaction aims to create a precision medicine company focused on advancing nebokitug through Phase 2 trials while leveraging Scipher's revenue-generating business.PharmExecPharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing AgreementChemomab Therapeutics and Scipher Medicine announced an all-stock merger to advance an anti-CCL24 antibody into an AI-guided Phase II rheumatoid arthritis trial. Separately, Teva entered a global licensing agreement with Polpharma Biologics for exclusive commercialization rights to a proposed ocrelizumab biosimilar across major markets. Both deals reflect ongoing consolidation and strategic positioning within the specialty pharma and biosimilars space.The Pharma LetterChemomab to merge with Scipher Medicine to advance AI-guided RA programIsraeli biotech Chemomab Therapeutics has agreed to merge with US precision medicine company Scipher Medicine to advance an AI-guided Phase II trial of nebokitug in rheumatoid arthritis. The transaction includes approximately $30 million in gross proceeds from a concurrent private placement and is expected to fund combined operations into the second half of 2028, with the merged entity valued at $150 million before financing.Pulse 2.0Chemomab Therapeutics And Scipher Medicine To Merge To Advance Nebokitug In AI-Powered RA TrialChemomab Therapeutics and Scipher Medicine announced a definitive merger agreement in a stock transaction, with the combined company expected to operate as Scipher Medicine Corporation and trade on Nasdaq under ticker SCIP. The merger will advance nebokitug, Chemomab's first-in-class anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial using Scipher's AI Network Medicine platform, with topline results expected in the first half of 2028. Current Scipher investors led by Northpond Ventures have committed approximately $30 million in gross cash proceeds as part of a concurrent private placement, with the combined company valued at $150 million.